Kathleen A. Dorritie, MD

home / authors / kathleen-a-dorritie-md

Articles

Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL

Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL

Kathleen A. Dorritie, MD
November 19th 2024

Kathleen A. Dorritie, MD, discusses 5-year of follow-up data from the CAPTIVATE trial in chronic lymphocytic leukemia and/or small lymphocytic lymphoma.

Read More

Kathleen A. Dorritie, MD

Dr Dorritie on Acalabrutinib With/Without Obinutuzumab in Treatment-Naive CLL

Kathleen A. Dorritie, MD
September 27th 2024

Kathleen A. Dorritie, MD, discusses acalabrutinib with or without obinutuzumab vs obinutuzumab plus chlorambucil in treatment-naïve CLL.

Read More

Kathleen A. Dorritie, MD

Dr Dorritie on Unanswered Questions Regarding Upfront Treatment Selection in CLL

Kathleen A. Dorritie, MD
July 3rd 2024

Kathleen A. Dorritie, MD, discusses unmet needs regarding upfront treatment selection in chronic lymphocytic leukemia.

Read More

Kathleen A. Dorritie, MD

Dr Dorritie on the NCRI-FLAIR Trial of Ibrutinib Plus Venetoclax in Previously Untreated CLL

Kathleen A. Dorritie, MD
May 24th 2024

Kathleen A. Dorritie, MD, discusses the significance of results from the phase 3 NCRI-FLAIR study in previously untreated chronic lymphocytic leukemia.

Read More

Kathleen ​A. Dorritie, MD

Dr. Dorritie on Determining Transplant Eligibility in Multiple Myeloma

Kathleen A. Dorritie, MD
November 24th 2020

Kathleen ​A. Dorritie, MD, discusses transplant eligibility in multiple myeloma.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need